Redbiotec AG

Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. Redbiotec was among the first companies to mimic complex viruses with the de novo viral particle generation as vaccine candidates. The company boosted the development of a vaccine against the Cytomegalovirus (CMV), being the first company to develop one of the key antigens. The CMV program was spun off as Redvax GmbH and Pfizer acquired a controlling interest for an undisclosed sum in January 2015. The transaction provided Pfizer with access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as IP and a technology platform related to a second, undisclosed vaccine program. Redbiotec kept its core technology for all further applications. Redbiotec has an ongoing program against Herpes simplex viruses and recently started to engineer microorganisms as diagnostic tools and therapies. As of 2017 Redbiotec remains in Schlieren.